Skip to main content
B

BRIM Biotechnology, Inc. — Investor Relations & Filings

Ticker · 6885 TW Professional, scientific and technical activities
Open in API
Filings indexed 8 across all filing types
Latest filing 2026-04-10 Share Issue/Capital Cha…
Country TW Taiwan
Listing TW 6885

About BRIM Biotechnology, Inc.

https://www.brimbiotech.com/

BRIM Biotechnology, Inc. specializes in the application of translational science to develop innovative therapies for unmet medical needs. The company utilizes its proprietary Pigment Epithelium-Derived Factor (PEDF) Derived Short Peptide (PDSP) technology platform, which leverages neurotrophic properties to stimulate cell proliferation, wound healing, and tissue regeneration. Its research pipeline primarily targets ophthalmology and degenerative conditions, featuring lead candidates such as BRM421 for dry eye syndrome, BRM424 for neurotrophic keratitis, and BRM521 for osteoarthritis. Operating through an integrated model, the company advances drug candidates to the proof-of-concept stage before pursuing strategic licensing and partnerships for late-stage development. BRIM also incorporates precision medicine and bioinformatics to explore combination therapies and enhance therapeutic outcomes.

Recent filings

Filing Released Lang Actions
115年4月變更登記
Share Issue/Capital Change Classification · 1% confidence The document is a capital structure disclosure from the Taiwan Market Observation Post System showing authorized capital, issued capital, and details of share capital changes (e.g., employee stock option conversion). This fits the Share Issue/Capital Change category rather than a general regulatory announcement or another report type.
2026-04-10 Chinese
公司基本資料
Regulatory Filings Classification · 1% confidence The document is a static corporate profile from Taiwan’s “公開資訊觀測站” showing stock code, company name, address, directors, share capital, listing dates, CPA firm, and other basic company data. It does not present financial results, meeting materials, management changes, or other specified report types but is a general regulatory disclosure of company information. As it does not fit into any more specific category, it is classified under the fallback Regulatory Filings (RNS).
2026-04-10 Chinese
公告本公司限制員工權利新股收回註銷完成變更登記
Share Issue/Capital Change Classification · 1% confidence The document is a formal announcement on the public information observatory (“公開資訊觀測站”) by a listed company 6885, detailing the completion of capital change registration due to the cancellation of restricted employee stock rights (new shares retrieval and cancellation). This is a share capital reduction/cancellation event, which falls under the category of share issue/capital change disclosures rather than an earnings release or management report. Therefore, the correct classification is SHA (Share Issue/Capital Change).
2026-04-09 Chinese
115年04月僑外投資持股
Regulatory Filings Classification · 1% confidence The document is a regulatory disclosure table – “僑外及大陸地區投資人投資持股情形統計表” – detailing foreign and mainland China investor holdings around a capital reduction event. It is not a full report (10-K, IR, etc.), nor an earnings announcement, proxy, or board change. It does not cross-shareholding thresholds for a major shareholding notice, nor is it simply announcing a report publication. Rather, it is a miscellaneous regulatory filing, so it falls under the fallback category of Regulatory Filings (RNS).
2026-04-09 Chinese
115年03月內部人持股異動(事後)
Director's Dealing Classification · 1% confidence The document is a detailed disclosure of insider (董事長、董事、獨立董事、總經理、副總經理等) shareholdings and month-on-month changes in their personal stock positions, provided by the listed company 全福生技 on Taiwan’s Public Information Observatory. It reports personal share transactions by directors and executives, which falls under insider dealing disclosures rather than company buybacks or major external shareholding notifications. Therefore, it should be classified as a Director’s Dealing (DIRS).
2026-04-08 Chinese
115年03月董事會成員及持股
Director's Dealing Classification · 1% confidence The document is a regulatory disclosure from the public information observation station listing shareholdings and pledge status of directors, independent directors, the general manager, and other insiders of 全福生技. It is an insider shareholding change report (“內部人持股異動事後申報表”), which falls under reports of personal share transactions by company directors and executives. This matches the “Director’s Dealing” category (DIRS).
2026-04-08 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.